Abbott Laboratories’ second quarter 2025 diagnostics revenue fell 1% year over year to $2.17 billion, pressured by rapid decreases in COVID-19 testing sales and volume-based procurement effects in China. The overall diagnostics segment was the only company business to decline, despite growth in underlying core laboratory business outside China. Abbott anticipates headwinds of $700 million from these factors, totaling over $1 billion including changes in HIV testing funding. Despite challenges, Abbott projects 7.5-8% organic full-year growth excluding COVID-19 testing and reported adjusted EPS guidance in line with market expectations.